

**MO HEALTHNET DRUG UTILIZATION REVIEW BOARD**

**January 17, 2018**

**Missouri Coalition for Community Behavioral Healthcare, 221 Metro Dr., Lower Level CEO Room, Jefferson City MO**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Charlene Heyde, RPh  
Sandra Bollinger, Pharm D  
Randy Beckner  
Stacy Mangum, Pharm D  
Ginger Nicol, MD, CEDS

**DUR BOARD MEMBER GUESTS**

Erica Prost, STLCOP  
Emily Klobe, UMKC School of Pharmacy  
Cherity Fulks, SIUE  
Regis Goad, Student

**DUR BOARD MEMBERS ABSENT**

Jennifer Passanise, FNP  
Glen Talboy, MD  
Kenneth Haller, MD

**OTHERS IN ATTENDANCE**

Mike Lafond, AbbVie  
Ashley Polce, AbbVie  
Evan Rushing, Alkermes  
Donna Osterlund, Genzyme  
Jim Bauman, Pfizer  
Phillip King, Pfizer  
Mike Holmes, Sunovion

Heather Maruska, United Healthcare  
Shefalie Patel, Wipro  
Geri Roling, Wipro

**MHD STAFF PRESENT**

Stephen Calloway, RPh, Director of Pharmacy  
Mark Roaseau, RPh, Clinical Pharmacist  
Frances (Franki) Moseley, Administrative Office Support Assistant  
Jenna McTeer, RN, Clinical Management  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager  
Angela Wilson, Manager, Band I

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Richard Pope, Pharm D, Magellan

<b>Welcome, Introductions and Opening Remarks</b>	Susan Abdel-Rahman, Pharm D, called the meeting to order. Stephen Calloway, RPh, facilitated the meeting on behalf of the MO HealthNet Division (MHD). Introductions were made all around.
<b>Minutes Review and Approval</b>	Minutes of the July 2017 DUR Board meeting were reviewed and approved as submitted. (See Roll Call Votes)
<b>Pharmacy Program/Budget Update</b>	Stephen Calloway, RPh, presented a brief power point presentation. The presentation contained graphs representing demographic information about MHD participants, drug expenditures by participant groups, drug class, and program. Information was also provided on selected drug expenditures and initiatives MHD is tracking and State Opioid activities.
<b>Old Business Implementation Schedule</b>	An updated copy of the Proposed Implementation Schedule for Edits, including PDL classes was included in the Members' meeting packet and provided as a handout to all attending. The Schedule included the PDL decisions to be implemented March 2018. Pending ratification, PDL decisions from December/January will be implemented March 2018. Schedules may be found on the MHD web page at <a href="http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf">http://dss.missouri.gov/mhd/cs/pharmacy/impsched.pdf</a>
<b>New Drug Review</b>	Stephen Calloway, RPH, reviewed the new drug products that were identified for the quarter July, August, September 2017, the recommended status within the clinical program. <ul style="list-style-type: none"> <li>• <b>Discussion</b> - A listing of products recommended for open access, clinical edit, preferred drug list (PDL) product, or continued prior authorization was provided in the Members' meeting packet, along with the Drug Prior Authorization Committee's actions/decisions.</li> <li>• <b>Decision</b> - The listing and recommendations were approved as part of a block vote by the DUR Board (See Roll Call Votes).</li> </ul>
<b>Clinical Edits</b>	
<b>Morphine Milligram Equivalents Accumulation</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>
<b>Benzodiazepines Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>
<b>Atypical Antipsychotics Step Therapy Clinical Edit</b>	<ul style="list-style-type: none"> <li>• <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>• <b>Public Hearing</b> – No comments entered.</li> <li>• <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>

<b>Psychiatric Polypharmacy Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>
<b>Dose Optimization Clinical Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>
<b>OTC/Dispensing Quantity Fiscal Edit</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, reviewed the criteria document, and recommended updates to approval and denial criteria.</li> <li>● <b>Public Hearing</b> – No comments entered.</li> <li>● <b>Decision</b> – After discussion of proposed criteria the clinical edit was approved. (See Roll Call Vote)</li> </ul>
<b>Preferred Drug List (PDL) Annual Review</b>	
<b>Alzheimer’s Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antiemetic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Antipsychotics: Long Acting Injectables (NEW)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Cox-II Inhibitor Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Fibromyalgia Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>GI Motility Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Movement Disorder Agents (NEW)</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>

<b>Neuropathic Pain Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Non-Ergot Dopamine Receptor Agonists</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes)</li> </ul>
<b>NSAID Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Opioid Dependence Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Opioid Emergency Reversal Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Opioid, Long-Acting Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Sedative Hypnotic Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Skeletal Muscle Relaxants</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Serotonin Receptor Agonists Triptans</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Tramadol-Like Agents</b>	<ul style="list-style-type: none"> <li>● <b>Discussion</b> – Stephen Calloway, RPh, presented the criteria document, reviewing preferred and non-preferred agents.</li> <li>● <b>Decision</b> – This edit was accepted and added to the block vote. (See Roll Call Votes).</li> </ul>
<b>Call Center Statistics Clinical Edit Summary Report</b>	A handout detailing pharmacy help desk call center activity was provided for all attending. Cyber Access Active User Counts and Logging Information reports detailing activity were also provided. Dr. Luke Boehmer presented updated Call Center Statistics for the Short Acting Single Agent Opioids and Short Acting Combination Opioids. Dr. Boehmer also presented utilization data documenting the impact of the edit changes on morphine equivalents and units dispensed.

<b>Conduent Update</b>	Dr. Luke Boehmer discussed the Call Center Statistics for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids both Pre-Implementation of the last dosing reductions and Post-implementation of the last dosage reductions. Dr. Boehmer discussed the Spend PMPM and Claims PMPM for the Short Acting Single Agent Opioids, Short Acting Combination Opioids, and Long Acting Opioids. Dr. Boehmer discussed the overall Claims trends for Opioids since 2009 and the trend of patients taking over the recommended max dose since 2009. Dr. Boehmer discussed the Respiratory Distress Incidence among patients taking Short Acting Single Agent Opioids, Short Acting Combo Opioids, Long Acting Opioids, and the Opioid Dependence Agents. Dr. Boehmer looked at data for patients who had an incidence of Respiratory Distress after receiving an Opioid. Dr. Boehmer also looked at data for patients who had another respiratory disease diagnosis along with the respiratory distress diagnosis. Dr. Luke Boehmer discussed last the FFS Overdose Incidence Report year over year since 2013. Dr. Luke Boehmer discussed the number of patients that had an ER visit due to an Overdose and the number of patients that were admitted to inpatient status as a result of an overdose.
<b>Preferred Drug List Announcement</b>	A handout of therapeutic categories to be reviewed for inclusion on the Preferred Drug List for the next phase and meeting was included in the meeting packet. This handout was also provided to all attendees and will be posted to the Division's web page: <a href="http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf">http://dss.mo.gov/mhd/cs/pharmacy/pdf/pdla.pdf</a>
<b>Program Utilization: Top 25 Drugs Summary</b>	Luke Boehmer, Pharm D, reviewed the Top 25 Drugs Summary Reports for the 1st, 2 <sup>nd</sup> , 3 <sup>rd</sup> , & 4th quarter 2017. Two versions were presented: one report ranked drug spend by dollars and the other by utilization/claims.
<b>Adjourn</b>	Susan Abdel-Rahman, Pharm D, made a motion to move to close the meeting under Section 610.021 (5),(14) to go into Executive Session for the sole purpose of discussing individual participant specific medical information. (See attached roll call vote). At the conclusion of this discussion the meeting was adjourned entertaining no further business, actions, or motions. (See attached roll call vote). The next DUR Board meeting is scheduled for April 18, 2018, at the <b>Missouri Coalition for Community Behavioral Healthcare, Lower Level CEO Room, 221 Metro Drive , Jefferson City MO.</b>

**Roll Call Votes – January 17, 2018**

<b>MEMBERS</b>	<b>MEETING MINUTES</b>	<b>ALL RECOMMENDATIONS BLOCK VOTE</b>	<b>CLOSED SESSION PURSUANT TO SECTION 610.021 SUBSECTION (14), (5)</b>	<b>ADJOURN EXECUTIVE SESSION</b>
Susan Abdel-Rahman, Pharm D	Y	Y	Y	Y
Charlene Heyde, RPh	Y	S,Y	Y	Y
Sandra Bollinger, Pharm D	Y	Y	Y	M
Kenneth Haller, MD	A	A	A	A
Glenn Talboy, MD	A	A	A	A
Jennifer Passanise, FNP	A	A	A	A
Stacy Mangum, Pharm D	M,Y	Y	M,Y	S,Y
Ginger Nicol, MD, CEDS	S,Y	M,Y	Y	Y
Randy Beckner, Pharm D	Y	Y	S	A

**M - motion to vote**  
**S - second to vote**  
**Y - yes to the vote**  
**N – no to the vote**  
**A - absent**

**Randy Beckner abstained on Non Ergot Dopamine Receptor Agents and Serotonin Receptor Agonists (Triptans)**

**EXECUTIVE SESSION**  
**October 18, 2017**

**DUR BOARD MEMBERS PRESENT**

Susan Abdel-Rahman, Pharm D – Board Chair  
Charlene Heyde, RPh  
Sandra Bollinger, Pharm D  
Randy Beckner, Pharm D  
Stacy Mangum, Pharm D  
Ginger Nicol, MD, CEDS

**DUR BOARD MEMBER GUESTS**

Erica Prost, STLCOP Student  
Emily Klobe, UMKC School of Pharmacy Student  
Cherity Fulks, SIUE Student  
Regis Goad, SIUE Student  
Rachael Young, SIUE Student

**DUR BOARD MEMBERS ABSENT**

Jennifer Passanise, FNP  
Kenneth Haller, MD  
Gen Talboy, MD

**MHD STAFF PRESENT**

Mark Roaseau, RPh, Clinical Pharmacist  
Stephen Calloway, RPh, Director of Pharmacy  
Angela Wilson, Manager, Band I  
Jenna McTeer, RN, Clinical Management  
Lisa Smith, Program Development Specialist  
Mitch Ruth, Fiscal Unit Manager  
Frances (Franki) Moseley, Administrative Office Support Assistant

**CONTRACTED STAFF PRESENT**

Joshua Moore, Pharm D, Conduent  
Katie Wilbers, Pharm D, Conduent  
Luke Boehmer, Pharm D, Conduent  
Richard Pope, Pharm D, Magellan

Minutes Review	There were no October minutes for the Executive Session to be approved as submitted.
Case Reviews	One Case for Review
Adjourn	Executive session